This document is scheduled to be published in the
Federal Register on 2026-09-25 and available online at
https://www.federalregister.gov/d/2026-19699, and on
https://govinfo.gov

3510-DS-P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-123-2026]

Foreign-Trade Zone (FTZ) 57, Notification of Proposed Production Activity; Eli Lilly and Company; (Drug Products); Concord, North Carolina

Eli Lilly and Company submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Concord, North Carolina within Subzone 57F. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on September 17, 2026.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website – accessible via www.trade.gov/ftz.

The proposed finished products include: Incretin-based therapy for blood glucose and weight management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; CGRP monoclonal antibody for migraine prevention drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi finished syringes; IL-17A monoclonal antibody for chronic inflammatory conditions drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Incretin-based therapy for blood glucose management in type 2 diabetes drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Multi-incretin therapy for weight and metabolic management drug product in dosage/packaged form in filled syringes, vials, or delivery

pens or semi-finished syringes; IL-13-targeted therapy for atopic dermatitis management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi finished syringes; IL-23-targeted therapy for inflammatory bowel disease management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; and Amyloid-targeted therapy for early Alzheimer's disease drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes (duty free).

The proposed foreign-status materials/components include: Incretin-based therapy for blood glucose and weight management drug substance; Incretin-based therapy for blood glucose and weight management drug product in vials or semi-finished syringes; CGRP monoclonal antibody for migraine prevention drug substance; CGRP monoclonal antibody for migraine prevention drug product in vials or semi-finished syringes; IL-17A monoclonal antibody for chronic inflammatory conditions drug substance; IL-17A monoclonal antibody for chronic inflammatory conditions drug product in vials or semi-finished syringes; Incretin-based therapy for blood glucose management in type 2 diabetes drug substance; Incretin-based therapy for blood glucose management in type 2 diabetes drug product in vials or semi-finished syringes; Multi-incretin therapy for weight and metabolic management drug substance; Multi-incretin therapy for weight and metabolic management drug product in vials or semi-finished syringes; IL-13-targeted therapy for atopic dermatitis management drug substance; IL-13-targeted therapy for atopic dermatitis management drug product in vials or semi-finished syringes; IL-23-targeted therapy for inflammatory bowel disease management drug substance; IL-23-targeted therapy for inflammatory bowel disease management drug product in vials or semi-finished syringes; Amylin receptor-targeted

therapy for weight management drug product in vials or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug substance; Amyloid-targeted therapy for early Alzheimer's disease drug product in vials or semi-finished syringes; Amyloid-targeted therapy for early Alzheimer's disease drug substance; Medicine delivery device, and parts thereof – including Cap Cartridge Holder, Dry Side Subassembly, Damping Cup, RNS Puller, Base Cap; Medicine delivery device needles; Glass vials; and Syringes (duty free).

The request indicates that certain materials/components are subject to duties under section 232 of the Trade Expansion Act of 1962 or section 301 of the Trade Act of 1974, depending on the country of origin. The applicable section 232 and section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status as described in 19 CFR 146.41.

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is **[INSERT DATE 40 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]**.

A copy of the notification will be available for public inspection in the "Online FTZ Information System" section of the Board's website.

For further information, contact John Frye at John.Frye@trade.gov.

Dated: September 22, 2026.

Colin Agostisi,
Executive Secretary.

[FR Doc. 2026-19699 Filed: 9/24/2026 8:45 am; Publication Date: 9/25/2026]